Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

(2016) Lena M. Kranz et al.   NATURE

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

(2015) Cornelia L Trimble et al.   LANCET

Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination

(2015) Benjamin Yang et al.   Cell and Bioscience

Challenges in Manufacturing Adenoviral Vectors for Global Vaccine Product Deployment

(2014) Jort Vellinga et al.   HUMAN GENE THERAPY

Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients

(2014) Tae Jin Kim et al.   Nature Communications

Differential In Vitro Immortalization Capacity of Eleven, Probable High-Risk Human Papillomavirus Types

(2013) D. M. Schutze et al.   JOURNAL OF VIROLOGY

The Papillomavirus E2 proteins

(2013) Alison A. McBride   VIROLOGY

Rational Design of DNA Vaccines for the Induction of Human Papillomavirus Type 16 E6- and E7-Specific Cytotoxic T-Cell Responses

(2012) Koen Oosterhuis et al.   HUMAN GENE THERAPY

Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer

(2012) Peng Guan et al.   INTERNATIONAL JOURNAL OF CANCER

Preclinical safety evaluation of DNA vaccines encoding modified HPV16 E6 and E7

(2012) F.E. Henken et al.   VACCINE

Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7

(2011) Koen Oosterhuis et al.   INTERNATIONAL JOURNAL OF CANCER

Proteasomal Degradation of p53 by Human Papillomavirus E6 Oncoprotein Relies on the Structural Integrity of p53 Core Domain

(2011) Xavier Bernard et al.   PLoS One

Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18

(2011) Li Zhao et al.   Virology Journal

The Novel Tuberculosis Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4+and CD8+T Cells in Adults

(2010) Brian Abel et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Cell-Mediated Immune Responses to Human Papillomavirus 16 E6 and E7 Antigens as Measured by Interferon Gamma Enzyme-Linked Immunospot in Women With Cleared or Persistent Human Papillomavirus Infection

(2010) Sepideh Farhat et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Human Papillomavirus 16-Associated Cervical Intraepithelial Neoplasia in Humans Excludes CD8 T Cells from Dysplastic Epithelium

(2010) C. L. Trimble et al.   JOURNAL OF IMMUNOLOGY

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults

(2010) J.E. Ledgerwood et al.   VACCINE

Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

(2009) Gemma G. Kenter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Surgery followed by Persistence of High-Grade Squamous Intraepithelial Lesions Is Associated with the Induction of a Dysfunctional HPV16-Specific T-Cell Response

(2008) P. J. de Vos van Steenwijk et al.   CLINICAL CANCER RESEARCH

Balancing selection and heterogeneity across the classical human leukocyte antigen loci: A meta-analytic review of 497 population studies

(2008) Owen D. Solberg et al.   HUMAN IMMUNOLOGY

Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions

(2008) Brooke E. Hoots et al.   INTERNATIONAL JOURNAL OF CANCER